TOP 200 Companies filing patents this week Companies with the Most Patent Filings (2010+)
Web
Oncomed Pharmaceuticals Inc patents (2015 archive)
Recent patent applications related to Oncomed Pharmaceuticals Inc. Oncomed Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Oncomed Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Oncomed Pharmaceuticals Inc, we're just tracking patents.
ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Oncomed Pharmaceuticals Inc-related inventors
Methods of treating ocular diseases
The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating ocular diseases. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4. ... Oncomed Pharmaceuticals Inc
Compositions and methods for treating and diagnosing cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies lgr5 as a protein over-expressed in solid tumor stem cell. ... Oncomed Pharmaceuticals Inc
Human notch receptor mutations and their use
The present invention provides the identification and characterization of notch mutations associated with enhanced receptor signaling. The present invention provides methods and kits for using the same. ... Oncomed Pharmaceuticals Inc
Methods for identifying and isolating cells expressing a polypeptide
The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. ... Oncomed Pharmaceuticals Inc
Methods of treating hematological malignancies with notch1 antibodies
Notch1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human notch1 and methods of treating chronic lymphocytic leukemia (cll), hairy cell leukemia, chronic myelogenous leukemia (cml), nonhodgkin lymphoma, diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), or cutaneous t-cell lymphoma (ctcl) in a subject, comprising administering a therapeutically effective amount of a notch1-binding antibody to the subject are also disclosed. ... Oncomed Pharmaceuticals Inc
Frizzled-binding agents and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. ... Oncomed Pharmaceuticals Inc
Notch binding agents and antagonists and methods of use thereof
The present invention relates to notch-binding agents and notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human notch receptor, such as notch2 and/or notch3, and inhibit tumor growth. ... Oncomed Pharmaceuticals Inc
Jagged-binding agents and uses thereof
The present invention relates to jagged-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of human jagged1 or human jagged2 and modulate jagged activity. ... Oncomed Pharmaceuticals Inc
Compositions and methods for diagnosing and treating cancer
Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-notch antibody in an amount effective to inhibit tumor growth.. ... Oncomed Pharmaceuticals Inc
Notch1 receptor binding agents and methods of use thereof
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. ... Oncomed Pharmaceuticals Inc
Compositions and methods for treating and diagnosing cancer
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies lgr5 as a protein over-expressed in solid tumor stem cells. ... Oncomed Pharmaceuticals Inc
Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
Methods for treating cancer comprising administering a dll4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a dll4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.. ... Oncomed Pharmaceuticals Inc
Vegf/dll4 binding agents and uses thereof
The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4. ... Oncomed Pharmaceuticals Inc
Rspo binding agents and uses thereof
The present invention relates to rspo-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human rspo proteins and modulate β-catenin activity. ... Oncomed Pharmaceuticals Inc
Rspo binding agents and uses thereof
The present invention relates to rspo-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human rspo proteins and modulate β-catenin activity. ... Oncomed Pharmaceuticals Inc
ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Oncomed Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Oncomed Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com
###